LGD-4033 and Telmisartan Interaction

Avoid
Mechanism-based 64% confidence

LGD-4033 and Telmisartan have a potentially harmful interaction with 64% confidence. Both LGD-4033 and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Telmisartan

Angiotensin II Receptor Blocker | Cardiac Protection On Cycle

Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling.

Half-life: ~24 hours Typical dose: 20-80 mg/day cardiovascular
ppar gamma blood pressure raisinghepatotoxicinsulin sensitizingteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Heart
moderate
Liver
moderate

Shared Safety Flags

2x 2 compounds raise blood pressure (LGD-4033, Telmisartan). Monitor BP daily and consider cardiovascular support.
2x 2 hepatotoxic compounds (LGD-4033, Telmisartan). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the teratogenic safety flag (LGD-4033, Telmisartan). Monitor accordingly.

Frequently Asked Questions

Can I take LGD-4033 with Telmisartan?

Combining LGD-4033 with Telmisartan is not recommended. Both LGD-4033 and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is LGD-4033 and Telmisartan safe together?

This combination carries significant risk. Both LGD-4033 and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between LGD-4033 and Telmisartan?

Both LGD-4033 and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and Telmisartan?

LGD-4033 has a half-life of ~24-36 hours and Telmisartan has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: LGD-4033 vs Telmisartan

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.